A summary of prospective trial efficacy results for papillary, chromophobe, unclassified, and translocation RCC for TKIs and mTOR inhibitors is provided in Table 1 and for ICI monotherapies and combination strategies in Table 2. This evidence concerns the gene MTOR and renal cell adenocarcinoma.